--- title: "Cogent Biosciences | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295404898.md" datetime: "2026-08-10T12:08:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295404898.md) - [en](https://longbridge.com/en/news/295404898.md) - [zh-HK](https://longbridge.com/zh-HK/news/295404898.md) generator: "portal-rs" --- # Cogent Biosciences | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EBIT: As of FY2026 Q2, the actual value is USD -95.19 M. ### Financial Overview Cogent Biosciences, Inc. reported a pro forma cash balance of $865.9 million, which is expected to fund operations into late 2028, including through potential FDA approvals and early commercial launch activities for bezuclastinib. As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $792.3 million, a decrease from $900.765 million as of December 31, 2025. #### Operating Expenses ##### Three Months Ended June 30 - **Research and development (R&D) expenses** were $70.811 million in Q2 2026, an increase from $62.203 million in Q2 2025. Non-cash stock compensation within R&D was $8.6 million in Q2 2026, up from $5.0 million in Q2 2025. - **General and administrative (G&A) expenses** were $31.827 million in Q2 2026, significantly higher than $13.379 million in Q2 2025. Non-cash stock compensation within G&A was $8.5 million in Q2 2026, compared to $4.8 million in Q2 2025. - **Total operating expenses** reached $102.638 million in Q2 2026, up from $75.582 million in Q2 2025. ##### Six Months Ended June 30 - **Research and development (R&D) expenses** were $146.176 million in H1 2026, compared to $125.232 million in H1 2025. - **General and administrative (G&A) expenses** were $60.069 million in H1 2026, up from $25.283 million in H1 2025. - **Total operating expenses** were $206.245 million in H1 2026, compared to $150.515 million in H1 2025. #### Loss from Operations - **Loss from operations** was -$102.638 million for Q2 2026, compared to -$75.582 million for Q2 2025. - For the six months ended June 30, the **loss from operations** was -$206.245 million in 2026, versus -$150.515 million in 2025. #### Other Income, Net ##### Three Months Ended June 30 - **Interest income** was $7.461 million in Q2 2026, an increase from $2.373 million in Q2 2025. - **Interest expense** was -$1.217 million in Q2 2026, compared to -$0.314 million in Q2 2025. - **Other income (expense), net** was -$0.011 million in Q2 2026, versus -$0.006 million in Q2 2025. - **Total other income, net** was $6.233 million in Q2 2026, up from $2.053 million in Q2 2025. ##### Six Months Ended June 30 - **Interest income** was $15.069 million in H1 2026, compared to $5.325 million in H1 2025. - **Interest expense** was -$2.430 million in H1 2026, versus -$0.314 million in H1 2025. - **Other income (expense), net** was -$0.151 million in H1 2026, compared to -$0.011 million in H1 2025. - **Total other income, net** was $12.488 million in H1 2026, up from $5.000 million in H1 2025. #### Net Loss - **Net loss** for Q2 2026 was -$96.405 million, compared to -$73.529 million for Q2 2025. - For the six months ended June 30, the **net loss** was -$193.757 million in 2026, versus -$145.515 million in 2025. #### Balance Sheet Data (as of June 30, 2026 vs. December 31, 2025) - **Working capital** was $745.524 million as of June 30, 2026, down from $846.402 million as of December 31, 2025. - **Total assets** were $834.546 million as of June 30, 2026, compared to $937.607 million as of December 31, 2025. - **Total liabilities** were $302.158 million as of June 30, 2026, slightly up from $301.236 million as of December 31, 2025. - **Total stockholders’ equity** was $532.388 million as of June 30, 2026, a decrease from $636.371 million as of December 31, 2025. ### Operational Highlights and Outlook Cogent Biosciences, Inc. submitted three New Drug Applications for bezuclastinib and onboarded a cross-functional customer-facing team in preparation for potential product launches. Key upcoming milestones include potential FDA approval of bezuclastinib for GIST patients by November 30, 2026, and for NonAdvSM patients by December 30, 2026. Additionally, the company plans to submit Investigational New Drug (IND) applications for CGT1815 and CGT1145, and complete dose escalation for CGT4255. ### Related Stocks - [COGT.US](https://longbridge.com/en/quote/COGT.US.md) ## Related News & Research - [HC Wainwright Brokers Decrease Earnings Estimates for COGT](https://longbridge.com/en/news/296613212.md) - [Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position](https://longbridge.com/en/news/296384188.md) - [Cogent Biosciences files for USD 400 million at-the-market stock offering](https://longbridge.com/en/news/295453309.md) - [Research Analysts Set Expectations for COGT Q1 Earnings](https://longbridge.com/en/news/296480559.md) - [J.P. Morgan Sticks to Its Buy Rating for Cogent Biosciences (COGT)](https://longbridge.com/en/news/279124539.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**